Danny Soon

On ceramides, other sphingolipids and impaired glucose homeostasis

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

Natural products: An evolving role in future drug discovery

The SPQ: A Scale for the Assessment of Schizotypal Personality Based on DSM-III-R Criteria

Interpreting population pharmacokinetic‐pharmacodynamic analyses – a clinical viewpoint

Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation

Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis

Natural products to drugs: natural product-derived compounds in clinical trials

Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular Basis

Exenatide

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Type 2 diabetes mellitus

Glycaemic control in type 2 diabetes: Targets and new therapies

Scales for physical and social anhedonia.

Assessing Anhedonia in Psychiatric Patients

Magical ideation as an indicator of schizotypy.

Development and validation of a multidimensional eating disorder inventory for anorexia nervosa and bulimia

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

Green synthesis of zinc oxide nanoparticles using Hibiscus subdariffa leaf extract: effect of temperature on synthesis, anti-bacterial activity and anti-diabetic activity

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

Exenatide

Inhibition of allergic inflammation by supplementation with 5-hydroxytryptophan

Emotion, attention, and the startle reflex.

Exenatide pharmacokinetics in healthy Chinese subjects

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

l-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI

Effect of Exenatide on the Steady‐State Pharmacokinetics of Digoxin

Hemodynamic Effects of Acute Administration of Atomoxetine and Methylphenidate

Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men

HYPOHEDONIA IN SCHIZOPHRENIA

PO428 COMPARATIVE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF LY2963016 INSULIN GLARGINE AND EU- AND US-APPROVED VERSIONS OF LANTUS® INSULIN GLARGINE IN HEALTHY SUBJECTS

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

PO427 COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS® IN HEALTHY SUBJECTS AT 2 DOSE LEVELS

Polar lipid derangements in type 2 diabetes mellitus: potential pathological relevance of fatty acyl heterogeneity in sphingolipids